Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Open-label uncontrolled trials of ponatinib (PACE) and bosutinib (NCT00261846; published by Khoury 2012) in CP-CML suggest ponatinib is more efficacious than bosutinib in third-line patients. However, lack of head-to-head randomized trials comparing third-line treatments poses a challenge for clinical and reimbursement decisions.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
